Cadila receives USFDA approval for Aripiprazole

Cadila has received final USFDA approval to market antipsychotic drug Aripiprazole tablets in US markets. The drug will be marketed in the strengths of 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg. It is an antipsychotic drug (atypical type), is used to treat mental/mood disorders such as bipolar disorder, schizophrenia, Tourette’s disorder, and irritability associated with autistic disorder.

It will be produced at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. Aripiprazole, It is also used in combination with other medications to treat depression. It works by helping restore the balance of certain natural chemicals in the brain (neurotransmitters).

Company Profile : Cadila Healthcare Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.


*